$BMRA
BIOMERICA INC Stock $bmra

$bmra Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000151316222000122 Filed on October 13, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$1.482M	$1.637M	$1.262M
YoY Change	-68.11%	29.74%	10.68%
Cost Of Revenue	$1.130M	$1.692M	$1.351M
YoY Change	-70.84%	25.29%	40.7%
Gross Profit	$351.9K	-$54.96K	-$88.97K
YoY Change	-54.41%	-38.23%	-149.43%
Gross Profit Margin	23.74%	-3.36%	-7.05%
Selling, General & Admin	$1.556M	$1.654M	$1.012M
YoY Change	21.28%	63.5%	-12.8%
% of Gross Profit	442.21%
Research & Development	$462.0K	$361.0K	$439.9K
YoY Change	-25.31%	-17.93%	-34.35%
% of Gross Profit	131.3%
Depreciation & Amortization	$16.00K	$20.00K	$34.72K
YoY Change	-52.87%	-42.4%	15.73%
% of Gross Profit	4.55%
Operating Expenses	$2.018M	$2.015M	$1.451M
YoY Change	6.12%	38.83%	-21.12%
Operating Profit	-$1.666M	-$2.070M	-$1.540M
YoY Change	47.47%	34.38%	-7.21%
Interest Expense	$41.25K	$30.00	$6.810K
YoY Change	496.1%	-99.56%	-31.9%
% of Operating Profit
Other Income/Expense, Net	$41.25K	$28.00	$6.805K
YoY Change		-99.59%
Pretax Income	-$1.625M	-$2.070M	-$1.534M
YoY Change	44.71%	34.97%	-7.06%
Income Tax	$1.254K	$1.957K	$9.020K
% Of Pretax Income
Net Earnings	-$1.626M	-$2.072M	-$1.543M
YoY Change	44.51%	34.31%	-6.51%
Net Earnings / Revenue	-109.72%	-126.57%	-122.25%
Basic Earnings Per Share	-$0.12	-$0.16	-$0.12
Diluted Earnings Per Share	-$0.12	-$0.16	-$124.1K
COMMON SHARES
Basic Shares Outstanding	13.43M shares	13.39M shares	12.43M shares
Diluted Shares Outstanding	13.46M shares	13.10M shares	12.43M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.067M	$6.075M	$4.997M
YoY Change	-29.62%	21.58%	-28.21%
Cash & Equivalents	$5.067M	$6.075M	$4.997M
Short-Term Investments
Other Short-Term Assets	$120.7K	$238.8K	$315.2K
YoY Change	-88.99%	-24.26%	-32.93%
Inventory	$2.061M	$1.922M	$2.862M
Prepaid Expenses
Receivables	$850.0K	$932.3K	$772.2K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.099M	$9.168M	$8.946M
YoY Change	-34.71%	2.48%	-31.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$236.7K	$227.9K	$1.778M
YoY Change	-86.09%	-87.18%	-8.82%
Goodwill
YoY Change
Intangibles	$157.7K	$160.8K
YoY Change
Long-Term Investments	$165.3K	$165.3K	$165.3K
YoY Change	0.0%	0.0%	-2.75%
Other Assets	$79.65K	$93.51K	$266.6K
YoY Change	-46.75%	-64.92%	-39.41%
Total Long-Term Assets	$1.809M	$1.882M	$2.570M
YoY Change	-24.81%	-26.77%	-7.21%
TOTAL ASSETS
Total Short-Term Assets	$8.099M	$9.168M	$8.946M
Total Long-Term Assets	$1.809M	$1.882M	$2.570M
Total Assets	$9.908M	$11.05M	$11.52M
YoY Change	-33.1%	-4.05%	-27.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$670.1K	$671.2K	$641.4K
YoY Change	-57.61%	4.65%	-49.5%
Accrued Expenses	$1.044M	$935.8K	$840.7K
YoY Change	3.41%	11.32%	58.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.763M	$1.758M	$1.482M
YoY Change	-62.81%	18.59%	-17.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$901.5K	$970.9K	$1.231M
YoY Change	-22.74%	-21.12%	-18.48%
Total Long-Term Liabilities	$901.5K	$970.9K	$1.231M
YoY Change	-22.74%	-21.12%	-18.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.763M	$1.758M	$1.482M
Total Long-Term Liabilities	$901.5K	$970.9K	$1.231M
Total Liabilities	$2.665M	$2.728M	$2.713M
YoY Change	-54.9%	0.57%	-18.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.80M	-$37.15M
YoY Change
Common Stock	$1.078M	$1.073M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.243M	$8.322M	$8.803M
YoY Change
Total Liabilities & Shareholders Equity	$9.908M	$11.05M	$11.52M
YoY Change	-33.1%	-4.05%	-27.53%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.626M	-$2.072M	-$1.543M
YoY Change	44.51%	34.31%	-6.51%
Depreciation, Depletion And Amortization	$16.00K	$20.00K	$34.72K
YoY Change	-52.87%	-42.4%	15.73%
Cash From Operating Activities	-$1.213M	-$1.573M	$75.84K
YoY Change	-190.34%	-2174.52%	-104.74%
INVESTING ACTIVITIES
Capital Expenditures	-$24.48K	$33.62K	-$77.52K
YoY Change	-50.66%	-143.37%	-13.87%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$24.48K	-$33.62K	-$77.52K
YoY Change	-50.66%	-56.63%	-13.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$804.6K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	238.1K	$1.778M	804.6K
YoY Change	-73.95%	120.92%	7946.1%
NET CHANGE
Cash From Operating Activities	-1.213M	-$1.573M	75.84K
Cash From Investing Activities	-24.48K	-$33.62K	-77.52K
Cash From Financing Activities	238.1K	$1.778M	804.6K
Net Change In Cash	-999.6K	$158.1K	802.9K
YoY Change	-145.28%	-80.32%	-147.79%
FREE CASH FLOW
Cash From Operating Activities	-$1.213M	-$1.573M	$75.84K
Capital Expenditures	-$24.48K	$33.62K	-$77.52K
Free Cash Flow	-$1.189M	-$1.607M	$153.4K
YoY Change	-185.37%	-1147.82%	-110.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Investments Investments	165324	usd
CY2022Q2	us-gaap	Investments Investments	165324	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21271	usd
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
CY2022Q3	dei	City Area Code CityAreaCode	949
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	645-2111
CY2022Q3	dei	Security12b Title Security12bTitle	COMMON STOCK, PAR VALUE $0.08
CY2022Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-08-31
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	001-37863
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	BIOMERICA, INC.
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-2645573
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	17571 Von Karman Avenue
CY2022Q3	dei	Trading Symbol TradingSymbol	BMRA
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13427651	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6075037	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5916983	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	383106	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	153231	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	932273	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	773818	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	981814	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	845549	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1921734	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2416447	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	238762	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	320283	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	9167806	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9427531	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1325561	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1305360	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	227908	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214487	usd
CY2022Q3	bmra	Accumulated Amortization Right Of Use Assets AccumulatedAmortizationRightOfUseAssets	791859	usd
CY2022Q2	bmra	Accumulated Amortization Right Of Use Assets AccumulatedAmortizationRightOfUseAssets	724802	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1234777	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1301834	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18994	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	160750	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	169516	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	93509	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95588	usd
CY2022Q3	us-gaap	Assets Assets	11050074	usd
CY2022Q2	us-gaap	Assets Assets	11374280	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	671240	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	972372	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	591948	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	646944	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	150523	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	50670	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	343889	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	341296	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1757600	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2011282	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	970890	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038284	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2728490	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3049566	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13406901	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13406901	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12867924	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12867924	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1072550	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1029432	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	44484752	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42446597	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-86463	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-73936	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37149255	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35077379	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8321584	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8324714	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11050074	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11374280	usd
CY2022Q3	us-gaap	Revenues Revenues	1637435	usd
CY2021Q3	us-gaap	Revenues Revenues	1261787	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1692390	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1350757	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-54955	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	-88970	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1653821	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1069855	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361171	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	381544	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2014992	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1451399	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2069947	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1540369	usd
CY2022Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	28	usd
CY2021Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6805	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6805	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2069919	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1533564	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1957	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9017	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2071876	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1542581	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13100407	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12426784	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13100407	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12426784	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2071876	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1542581	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-12527	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-5613	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2084403	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1548194	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	9227023	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3895	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	800710	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-5613	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	319622	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1542581	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	8803056	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8324714	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13950	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1763568	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-12527	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	303755	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2071876	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8321584	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2071876	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1542581	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28971	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34722	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	229875	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-94891	usd
CY2022Q3	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	136265	usd
CY2021Q3	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	179744	usd
CY2022Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	303755	usd
CY2021Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	319622	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	67057	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	62897	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	388330	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-777752	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-358448	usd
CY2021Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-164732	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-81521	usd
CY2021Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-55069	usd
CY2022Q3	bmra	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-64801	usd
CY2021Q3	bmra	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-55649	usd
CY2022Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2076	usd
CY2021Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2431	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-301132	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	58024	usd
CY2022Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-54996	usd
CY2021Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	118826	usd
CY2022Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	99853	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1573314	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	75836	usd
CY2021Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	72375	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33623	usd
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5141	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33623	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-77516	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1810927	usd
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	838333	usd
CY2022Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47359	usd
CY2021Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	37622	usd
CY2022Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13950	usd
CY2021Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3895	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1777518	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	804606	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-12527	usd
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-5613	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	158054	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	797313	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5916983	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4199311	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6075037	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4996624	usd
CY2022Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	1957	usd
CY2021Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	9017	usd
CY2022Q3	bmra	Write Off Of Intangible Assets Cost WriteOffOfIntangibleAssetsCost	6489	usd
CY2022Q3	bmra	Write Off Of Intangible Assets Accumulated Amortization WriteOffOfIntangibleAssetsAccumulatedAmortization	850	usd
CY2022Q3	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-FAMILY:"Times New Roman",serif">NOTE 1: BASIS OF PRESENTATION</span></b></p><p style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is</span><span style="FONT-SIZE:10pt"> a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care </span><span style="FONT-SIZE:10pt; COLOR:black">(physicians' offices and over-the-counter through drugstores and online)</span><span style="FONT-SIZE:10pt"> and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases</span><span style="FONT-SIZE:10pt; COLOR:black">. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The</span><span style="FONT-SIZE:10pt"> Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (“DGT”) products based on our InFoods<sup>®</sup> Technology platform that treat gastrointestinal diseases, such as irritable bowel syndrome (“IBS”), and other inflammatory diseases. These InFoods<sup>®</sup> based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using this patented InFoods Technology is our InFoods® IBS product which uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult to manage dietary restrictions, the InFoods® IBS product works by identifying a patient’s above normal immunoreactivity to specific foods. A food identified as positive and causing an abnormal immune response in the patient is simply removed from the diet to help alleviate IBS symptoms. We are currently in discussions with key gastroenterology (GI) physician groups who are interested in offering this product to their patients. As such, we are expecting to begin generating revenues from the launch of our InFoods<sup>®</sup> IBS product during our fiscal third quarter. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians' offices and over-the-counter at Walmart, Amazon, and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic<span style="COLOR:black">, in March 2020 we</span> began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we initially offered a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues <span style="COLOR:black">in fiscal 2022</span> and 2023 have come from international sales of our COVID-19 antigen tests that use a patient’s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand, less than 12% of our revenues during the three months ended August 31, 2022 were from sales of our COVID-19 related products. <span style="COLOR:black"> </span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Our non-COVID-19 products that accounted for over 88% of our revenues during the three months ended August 31, 2022, are primarily focused on gastrointestinal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country’s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:10pt; FONT-FAMILY:"Times New Roman"; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-FAMILY:"Times New Roman",serif; COLOR:black">The unaudited consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The accompanying interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2022. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended August 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2023. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC on August 29, 2022. Management has evaluated all subsequent events and transactions through the date of filing this report.</span></p>
CY2022Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">ACCOUNTING ESTIMATES</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p>
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6075000	usd
CY2022Q3	bmra	Working Capital WorkingCapital	7410000	usd
CY2020Q3	bmra	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	90000000	usd
CY2021Q1	bmra	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	15000000	usd
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9600000	shares
CY2022Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><b><span style="FONT-SIZE:10pt">CONCENTRATION OF CREDIT RISK</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. <span style="COLOR:black">As of August 31, 2022,</span> the Company had approximately $5,834,000 of uninsured cash. <span style="COLOR:black">The Company does not believe it is exposed to any significant credit risks.</span></span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt">Consolidated net sales were approximately $1,637,000 for the <span style="COLOR:black">three months ended August 31, 2022, as compared to $1,262,000 for the three months ended August 31, 2021. </span>For <span style="COLOR:black">the three months ended August 31, 2022 and 2021,</span> the Company had <span style="COLOR:black">two</span> key customers who are located in foreign countries which accounted <span style="COLOR:black">for 64%</span> and <span style="COLOR:black">60%</span> of net consolidated sales, respectively. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">Total gross receivables on August 31, 2022 and May 31, 2022 were approximately $1,315,000 and $927,000, respectively. On August 31, 2022</span><span style="FONT-SIZE:10pt"> and <span style="COLOR:black"> May 31, 2022,</span> the Company had two and <span style="COLOR:black">one</span> key customers who are located in foreign countries which accounted for a total of 67% and <span style="COLOR:black">50%,</span> respectively, of gross accounts receivable. </span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"><span style="FONT-SIZE:10pt; COLOR:black">For the three months ended August 31, 2022 and 2021, the</span><span style="FONT-SIZE:10pt"> Company had one <span style="COLOR:black">k</span>ey vendor which accounted for 9% <span style="COLOR:black">and 17%</span> of the purchases of raw materials, respectively. <span style="COLOR:black">As of August 31, 2022 and May 31, 2022,</span> the Company had one and two key vendors which accounted for 11% <span style="COLOR:black">and 69%, respectively</span>, of accounts payable.</span></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in 2.7pt 0in 0in"> </p>
CY2022Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5834000	usd
CY2022Q3	us-gaap	Revenues Revenues	1637000	usd
CY2021Q3	us-gaap	Revenues Revenues	1262000	usd
CY2022Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	1315000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	927000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	383000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	153000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1262000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	239000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	320000	usd
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1732000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1717000	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	723000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	763000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	449000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	782000	usd
CY2022Q3	us-gaap	Inventory Gross InventoryGross	2904000	usd
CY2022Q2	us-gaap	Inventory Gross InventoryGross	3262000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	846000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1922000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	2416000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	982000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	846000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000	usd
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7402000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	304000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	320000	usd
CY2022Q3	us-gaap	Proceeds From Customers ProceedsFromCustomers	151000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1637000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	382000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6967000	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	18000	usd
CY2021Q3	us-gaap	Advertising Expense AdvertisingExpense	8000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2022Q3	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><b><span style="FONT-SIZE:10pt; COLOR:black">RECLASSIFICATIONS</span></b></p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"> </p><p style="FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0in"><span style="FONT-SIZE:10pt; COLOR:black">Certain comparative figures in the August 31, 2021 condensed consolidated statement of operations have been reclassified to conform to the current period presentation. </span></p>
CY2022Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2022Q3	us-gaap	Revenues Revenues	1637000	usd
CY2021Q3	us-gaap	Revenues Revenues	1262000	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	22000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	78000	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	78000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	86000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7D
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	354000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	364000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	375000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	387000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1488000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	173000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1315000	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther		usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther		usd
CY2021Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2021Q3	bmra	Write Off Of Intangible Assets Cost WriteOffOfIntangibleAssetsCost		usd
CY2021Q3	bmra	Write Off Of Intangible Assets Accumulated Amortization WriteOffOfIntangibleAssetsAccumulatedAmortization		usd
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000073290

Files In Submission

Name	View Source	Status
0001513162-22-000122-index-headers.html	Edgar Link	pending
0001513162-22-000122-index.html	Edgar Link	pending
0001513162-22-000122.txt	Edgar Link	pending
0001513162-22-000122-xbrl.zip	Edgar Link	pending
bmra-20220831.htm	Edgar Link	pending
bmra-20220831.xsd	Edgar Link	pending
exhibit31_1.htm	Edgar Link	pending
exhibit31_2.htm	Edgar Link	pending
exhibit32_1.htm	Edgar Link	pending
exhibit32_2.htm	Edgar Link	pending
exhibit3_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
bmra-20220831_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmra-20220831_lab.xml	Edgar Link	unprocessable
bmra-20220831_pre.xml	Edgar Link	unprocessable
bmra-20220831_def.xml	Edgar Link	unprocessable
bmra-20220831_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRA
BIOMERICA INC Stock $bmra

2022 Q4 Form 10-Q Financial Statement

#000151316222000122 Filed on October 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA BIOMERICA INC Stock $bmra

2022 Q4 Form 10-Q Financial Statement

#000151316222000122 Filed on October 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA
BIOMERICA INC Stock $bmra